Analytic results in a study of Cognition Therapeutic’s CT1812, a drug targeting mild-to-moderate Alzheimer’s disease, indicates a reduction in the YKL-40, a biomarker for inflammation associated with Alzheimer’s.
Analytic results in a study of Cognition Therapeutic’s CT1812, a drug targeting mild-to-moderate Alzheimer’s disease, indicates a reduction in the YKL-40, a biomarker for inflammation associated with Alzheimer’s.